Yuqing Chen

Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.

Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.

Journal: Hematological oncology

Published: April 27, 2026

Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy.

Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy.

Journal: Frontiers in immunology

Published: June 20, 2025

Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study.

Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study.

Journal: The Lancet. Haematology

Published: May 15, 2025

Identification of the IFN-γ/IL-4 ratio as a prognostic biomarker and development of an immune-related prognostic model in diffuse large B-cell lymphoma.

Identification of the IFN-γ/IL-4 ratio as a prognostic biomarker and development of an immune-related prognostic model in diffuse large B-cell lymphoma.

Journal: BMC cancer

Published: April 30, 2025

CD20-positive peripheral T-cell lymphoma not otherwise specified: a case series and review of the literature.

CD20-positive peripheral T-cell lymphoma not otherwise specified: a case series and review of the literature.

Journal: Frontiers in oncology

Published: December 31, 2024

High Red Blood Cell Distribution Width to Platelet Ratio is an Independent Poor Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.

High Red Blood Cell Distribution Width to Platelet Ratio is an Independent Poor Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.

Journal: Discovery medicine

Published: April 27, 2023

Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era.

Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era.

Journal: Medicine

Published: March 23, 2021

The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer.

The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer.

Journal: OncoTargets and therapy

Published: December 01, 2019

Prognostic Significance Of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era.

Prognostic Significance Of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era.

Journal: Cancer management and research

Published: August 17, 2019

Bacteria-Derived Recombinant Human ANGPTL8/Betatrophin Significantly Increases the Level of Triglyceride.

Bacteria-Derived Recombinant Human ANGPTL8/Betatrophin Significantly Increases the Level of Triglyceride.

Journal: The protein journal

Published: April 01, 2019

LncRNA LINP1 regulates acute myeloid leukemia progression via HNF4α/AMPK/WNT5A signaling pathway.

LncRNA LINP1 regulates acute myeloid leukemia progression via HNF4α/AMPK/WNT5A signaling pathway.

Journal: Hematological oncology

Published: March 29, 2019

Effects of Decitabine on the proliferation of K562 cells and the expression of DR4 gene.

Effects of Decitabine on the proliferation of K562 cells and the expression of DR4 gene.

Journal: Saudi journal of biological sciences

Published: August 02, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026